A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.

Inclusion Criteria:

• Informed consent of parent or legally acceptable representative of participant andchild assent, as age-appropriate must be obtained before any trial relatedactivities

• The parent or legally acceptable representative of the child must sign and date theInformed consent form (according to local requirements)

• The child must sign and date child assent form or provide oral assent (if requiredaccording to local requirements)

• Prepubertal children: a) Boys: Age more than or equal to 2 years and 26 weeks andless than or equal to 11.0 years at the time of signing informed consent.

• Testis volume less than 4 ml. b) Girls: Age more than or equal to 2 years and 26weeks and less than or equal to 10.0 years at the time of signing informed consent.Tanner stage 1 for breast development (no palpable glandular breast tissue)

• Confirmed diagnosis of growth hormone deficiency determined by two different growthhormone stimulation tests performed within 12 months prior to randomisation, definedas a peak growth hormone level of less than or equal to 10.0 ng/ml using the WHOInternational Somatropin 98/574 standard

• If only one growth hormone stimulation test is available before screening, thenconfirmation of growth hormone deficiency by second and different growth hormonestimulation test must be done

• For children with at least 2 additional pituitary hormone deficiencies (other thangrowth hormone deficiency) only one growth hormone stimulation test is needed

• Impaired height defined as at least 2.0 standard deviations below the mean heightfor chronological age and gender according to Chinese general population standardsat screening

• Impaired height velocity defined as annualised height velocity at screening lessthan 7cm/year for subjects between 2.5 and 3 years old and less than 5 cm/year forsubjects from 3 years and above calculated over a time span of minimum 3 months andmaximum 18 months prior to screening according to Chinese guideline and expertconsensus on children with short stature and GH therapy

• No prior exposure to growth hormone therapy or IGF-I treatment

• Bone age less than chronological age at screening

• Body Mass Index more than 5th and less than 95th percentile, Body Mass Index-for-agegrowth charts according to Chinese general population standards.

• IGF-I < -1.0 SDS at screening, compared to age and gender normalized range measuredat central laboratory

• No intracranial tumour confirmed by magnetic resonance imaging or computertomography scan. An image or scan taken within 9 months prior to screening can beused as screening data if the medical evaluation and conclusion is available

Exclusion Criteria:

• Known or suspected hypersensitivity to trial product(s) or related products.

• Previous participation in this trial. Participation is defined as randomisation.

• Receipt of any investigational medicinal product within 3 months before screening orparticipation in another clinical trial before randomisation

• Any known or suspected clinically significant abnormality likely to affect growth orthe ability to evaluate growth with standing height measurements:

• Turner Syndrome (including mosaicisms)

• Chromosomal aneuploidy and significant gene mutations causing medical "syndromes"with short stature, including but not limited to Laron syndrome, Noonan syndrome,Prader-Willi Syndrome, abnormal SHOX-1 gene analysis or absence of GH receptors

• Significant spinal abnormalities including but not limited to scoliosis, kyphosisand spina bifida variants

• Congenital abnormalities (causing skeletal abnormalities), including but not limitedto Russell-Silver Syndrome or skeletal dysplasias

• Family history of skeletal dysplasia

• Children born small for gestational age (birth weight 10th percentile of therecommended gender-specific birth weight for gestational age according to nationalstandards in China5

• Children diagnosed with diabetes mellitus or screening values from centrallaboratory of

1. fasting plasma glucose more than or equal to 126 mg/dl (7.0 mmol/L) or

2. HbA1c more than or equal to 6.5 %

• Current inflammatory diseases requiring systemic corticosteroid treatment for longerthan 2 consecutive weeks within the last 3 months prior to screening

• Children requiring inhaled glucocorticoid therapy at a dose greater than 400 µg/dayof inhaled budesonide or equivalents for longer than 4 consecutive weeks within thelast 12 months prior to screening

• Concomitant administration of other treatments that may have an effect on growth,e.g. but not limited to methylphenidate for treatment of attention deficithyperactivity disorder (ADHD)

• Diagnosis of attention deficit hyperactivity disorder

• Prior history or presence of malignancy including intracranial tumours

• Prior history or known presence of active Hepatitis B or Hepatitis C (exceptions tothis exclusion criterion is the presence of antibodies due to vaccination againstHepatitis B)

• Any clinically significant abnormal laboratory screening tests, as judged by thestudy doctor

• Any disorder which, in the opinion of the study doctor, might jeopardiseParticipant's safety or compliance with the protocol

• The participant or the parent/legally acceptable representative is likely to benon-compliant in respect to trial conduct, as judged by the study doctor

• Children with hypothyroidism and/or adrenal insufficiency not on adequate and stablereplacement therapy for at least 90 days prior to randomisation.